In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $61.68, marking a -1.03% move from the previous day.

Viking Therapeutics, Inc.'s stock surged 1,500% on the promising obesity drug VK-2735, with Phase 3 trials and potential for ...

We recently compiled a list of the 10 Best Performing Small-Cap Stocks in 2024. In this article, we will look at where Viking ...

Viking Therapeutics VKTX has outperformed the market over the past 5 years by 41.66% on an annualized basis producing an ...

I'm bullish on Viking Therapeutics' weight-loss drug, but warn of risks and competition ahead. Click here to read my most ...

Viking Therapeutics (NASDAQ: VKTX) has captured the attention of investors, with its stock price skyrocketing over 400% in ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Investors with a lot of money to spend have taken a bearish stance on Viking Therapeutics (NASDAQ:VKTX). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $70.47 which represents a slight increase of $2.31 or 3.39% from the prior close of $68.16. The stock opened at $69.5 and ...

That's the big thrill about owning Viking Therapeutics. If the company's GLP-1 treatment, referred to as just VK2735 for now, obtains approval, this already hot stock could become an even more ...

The much smaller Viking Therapeutics has a promising weight loss drug that is entering phase 3 trials. These two stocks could be rivals in the intense GLP-1 space in the future. Investing into ...